Severe neutropenia in a breastfed infant: a case report and discussion of the differential diagnosis

Leonie van den Broek¹
Jutte van der Werff-ten Bosch²
Pieter-Jan Cortoos³
Susanne van Steijn¹
Machiel van den Akker¹,²

¹Department of Pediatrics, Queen Paola Children’s Hospital, Antwerp, Belgium; ²Department of Pediatric Hematology Oncology, UZ Brussels, Brussels, Belgium; ³Pharmacy, UZ Brussels, Brussels, Belgium

Abstract: Neonatal neutropenia is regularly seen with variable etiology. We describe a breastfed infant with maternal medication use as a probable cause of neonatal neutropenia. An 8 days old exclusively breastfed female infant of Arab-Berber descent was referred to our hospital because of an infection of the umbilicus. Complete blood count showed a picture of severe isolated neutropenia. After initiating intravenous antibiotic treatment, the infection quickly resolved, but the isolated neutropenia persisted. Bone marrow aspiration indicated severe congenital neutropenia. The mother was known to have Crohn’s disease, treated with methylprednisolone and adalimumab up to 3 months before delivery, and latent tuberculosis, for which she used isoniazid postnatally. Breast-feeding was terminated and filgrastim was started, with an increase of the neutrophilic count. After several weeks, filgrastim could be terminated. Bone marrow and complete blood count were repeated and were completely normal. This case report describes a very young breastfed female infant with severe neutropenia, causing an infection, in which maternal adalimumab use could not be excluded as a possible cause. Maternal isoniazid use is highly unlikely.

Keywords: congenital neutropenia, neonate, breast-feeding, adalimumab, isoniazid

Introduction
Neutrophils are the most abundant white blood cells in blood and play a critical role in recruiting and activating cells of the immune system, besides being a key player in the frontline defense against invading pathogens as part of the innate immune system. Reduction in neutrophils below an absolute count of 0.5×10⁹/L is termed severe neutropenia or agranulocytosis.¹

Neutropenia can be the result of a decreased production of neutrophils, an increased neutrophil destruction, or a combination of these mechanisms (Box 1).² One of the causes is drug induced. In drug-induced immune neutropenia, drug-dependent antibodies are formed against neutrophil membrane glycoprotein, causing neutrophil destruction. Severe neutropenia or agranulocytosis associated with exposure to nonchemotherapy drugs is seen in up to 15.4 cases per million population per year.² We report a very young breastfed female infant with severe neutropenia, in which adalimumab and isoniazid (INH) were used by the mother.

Case presentation
An 8 days old exclusively breastfed female infant was referred to our hospital because of an infection of the umbilicus without fever. She was the second child of nonconsanguine-
Physical examination of the neonate was, besides a local infection of the umbilicus, normal for her age. No (skeletal) malformations, cutaneous, or nail abnormalities; hepatosplenomegaly; or hypotonia were noted. However, complete blood count showed a picture of severe isolated neutropenia (hemoglobin 18.2 g/dL, mean corpuscular volume 97, platelets 254×10^9/L, leukocytes 7.56×10^9/L, and absolute neutrophil count [ANC] 0.04×10^9/L; C-reactive protein 73.1 mg/L). The child was admitted and broad-spectrum intravenous antibiotic treatment (ampicillin and cefotaxime) was started. The infection improved; however, the isolated neutropenia persisted. No viral etiology (TORCH, which includes Toxoplasmosis, Other [syphilis, varicella-zoster, parvovirus B19], Rubella, cytomegalovirus, and herpes infections), paramyxovirus, influenza, respiratory syncytial virus, and adenovirus) could be demonstrated. Testing for antineutrophil antibodies was not done, as the tests often show false-positive and false-negative results. Bone marrow aspiration revealed a severe dysgranulopoiesis, characterized by a maturation stop after the meta-/myelocyte stage (Figure 1), indicating severe congenital neutropenia. Maternal usage of adalimumab during pregnancy can cause neutropenia because it can cross the placenta from the maternal circulation into the fetal circulation.
Also, agranulocytosis due to INH, used by the mother while breast-feeding, could not be excluded. Tuberculosis was excluded in the child, and the complete blood count of the mother did not show neutropenia. As a probability scale, we use the Naranjo algorithm, and this case was scored for both medications separately. INH was scored “3,” while adalimumab was scored “4,” both as a “possible” likelihood to be responsible for the neutropenia (Naranjo scores: 9 or 10 indicate “definitely”; 5–8 rate the likelihood as “probable”; 1–4 “possible”; <1 “doubtful”).

Breast-feeding was terminated, and filgrastim (Neupogen®, Amgen Inc., Thousand Oaks, CA, USA) 5 µg/kg subcutaneously was started. A very slow increase of ANC was seen, and so filgrastim dose was increased to 10 µg/kg subcutaneously, with good improvement. ANC increased to a maximum of $35.85 \times 10^9$/L. Two months after birth, filgrastim was terminated which, initially, led to a decrease of ANC, before it stabilized in the normal range (Figure 2). Two weeks after terminating, the filgrastim a new bone marrow aspiration (Figure 1) and a complete blood count was repeated. Both were normal, which excluded severe congenital neutropenia.

Discussion
Adalimumab is a chimeric, monoclonal immunoglobulin G1 antibody directed against human TNF-α. Neutropenia is a common adverse reaction and may occur in up to 16% of patients receiving anti-TNF therapies, possibly due to a direct toxic effect on bone marrow. Adalimumab can cross the placenta from the maternal circulation into the fetal circulation, and peak levels (fetus) are reached during the third trimester of pregnancy. Consequently, these infants may be at increased risk for infection. Elimination of adalimumab is relatively long, half-life is about 2 weeks.

In our case, the mother did not use adalimumab during the third trimester. Despite this, a case series demonstrated that significant levels of anti-TNF agents can be measured in cord blood, even when adalimumab was discontinued 8 weeks before delivery, and can be 2- to 3-fold higher than in the peripheral blood of the mother.

In 2014, Guiddirt et al reported four cases of severe neutropenia, all complicated by a skin infection, after maternal use of infliximab, which has similar anti-TNF-α activity as adalimumab, but a shorter half-life of 7–12 days. Similarly to our case, anti-TNF therapy was not given during the third trimester. We did not measure adalimumab levels in the mother or in the child. However, as far as we know, there is no other literature which describes a neonatal neutropenia due to the use of adalimumab during pregnancy.

INH, a pyridine derivative of nicotinamide, is the most widely used first-line anti-tuberculosis drug and the mainstay in the treatment of latent tuberculosis. It is excreted in breast milk at relatively small concentrations and is considered to be compatible with breast-feeding by the American

Figure 1 Microscopic view of the bone marrow aspirate.
Notes: The upper picture shows a severe dysgranulopoiesis, characterized by a maturation stop after meta-/myelocyte stage, before starting filgrastim. The lower picture shows a normal bone marrow of our patient 2 weeks after terminating filgrastim.

Figure 2 ANC (cells/µL) of the patient (the arrows symbolize the start and the terminating of filgrastim) over several months.
Abbreviation: ANC, absolute neutrophil count.
Academy of Pediatrics and Centers for Disease Control and Prevention. Well-known adverse reactions of INH are an asymptomatic elevation of serum liver enzyme concentrations, peripheral neuropathy, and hepatotoxicity. Neutropenia is a known adverse reaction, but less often described. INH is excreted in breast milk at relatively small concentrations, but limited data are available about the subsequent exposure to the nursing infant. Normally, peak plasma concentrations of INH are achieved around one hour after ingestion and a similar trend is seen in breast milk, indicating that INH is quickly absorbed and transferred to breast milk with a mean milk: plasma ratio of 0.9. The mean relative dose of INH (1.2%) transmitted to the infant via breast milk is below the 10% notional level of concern. Under normal circumstances, these amounts of drug transfer to breast milk are not directly toxic since they are much lower than the INH dose prescribed to the infant as a prophylactic dose of 10 µg/kg. These data suggest that INH therapy is safe during breast-feeding.

However, pyridoxine supplements (1–2 mg/kg) are still recommended for breastfed infants if the mother uses INH. Although concentrations are low and toxic concentrations are rarely reached, pharmacological activity is possible. Toddywalla et al. reported that INH is capable of suppressing hepatic drug metabolizing activity in infants of mothers on chronic therapy, and Pariente-Khayat et al. reported that the maturation of N-acetyltansferase 2, which is the main route of metabolizing INH, occurs in the first 4 years of life.

Finally, the rate of acetylation INH is also genetically determined with a bimodal distribution of slow and fast acetylators. Given the fact that the slow acetylator phenotype is the most common (72%) one in Moroccan/North-African populations, it is very well possible that for the mother peak concentrations in plasma and breast milk have been high and half-life time prolonged. Still, we cannot explain the severe neutropenia due to the most likely insignificant INH exposure to the infant via breast milk, which has been described by Garessus et al. When we consequently rule out INH as a possible cause of the congenital neutropenia, the Naranjo score of adalimumab will change to “7,” a “probable” likelihood to be responsible for the neutropenia.

Although we realize a neonatal alloimmune neutropenia provoked by the maternal production of neutrophil-specific allo-antibodies is a more common cause, and, as said before, unfortunately we cannot prove that the persistence of adalimumab is the cause of the severe neutropenia in our child, we think this may be a good explanation. We would like to call for awareness of the side effects of the use of adalimumab in pregnancy, even in the first and second trimester. For each case, an individual risk/benefit analysis is advised. If INH-induced neutropenia is suspected, it is wise to examine the INH concentration in plasma and breastmilk before intervening in the INH treatment of the mother.

Conclusion
Adalimumab can cross the placenta from the maternal circulation into the fetal circulation, and peak levels are reached during the third trimester of pregnancy. Despite the advice of using adalimumab only in the first and second trimester, significant levels of anti-TNF agents are possible.

INH is excreted in breast milk at relatively small concentrations, and so it is considered to be compatible with breast-feeding. Toxic concentrations are rarely reached, but pharmacologically active plasma concentrations in breastfed infants due to suppressing hepatic drug metabolizing activity and N-acetyltansferase 2 immaturity in infants are theoretically possible. No evidence is found in the literature to support this assumption yet.

We reported an exclusively breastfed infant with severe neutropenia and infection possibly due to maternal adalimumab, which illustrates that thoughtfulness with the prescription of adalimumab in pregnancy, even in the first and second trimester, is important. For each case, an individual risk/benefit analysis is advised.

Author contributions
Leonie van den Broek drafted the initial manuscript. Pieter-Jan Cortoos participated in the writing of the manuscript. Machiel van den Akker carried out the initial analyses and coordinated and supervised the writing of the manuscript. Jutte van der Werfften Bosch, Pieter-Jan Cortoos, Susanne van Steijn, and Machiel van den Akker critically reviewed the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References